Filing summary
Filing identity and period: The supplied filing is Stellar Biotechnologies, Inc.’s unaudited Form 10-Q for the three months ended December 31, 2018 (its fiscal 2019 first quarter), not an Edesa Biotech filing. The filing describes a company that develops, manufactures and sells Keyhole Limpet Hemocyanin (KLH) for biotechnology, pharmaceutical and research customers. Amounts below are in U.S. dollars.
Financial performance and position
- Revenue: $53,033, versus $20,487 in the prior-year quarter, an increase attributed primarily to sales of higher-value clinical-grade KLH. Revenue remained limited and variable with customers’ clinical-development activity.
- Profit and margins: Net loss was $1.406 million, compared with $1.401 million. Operating loss was $1.406 million versus $1.390 million. Gross profit, calculated as sales less cost of sales, was $25,040, or approximately 47% of sales; the comparable prior-period calculation is $17,686, or approximately 86%. The small sales base makes these margins sensitive to product mix and timing.
- Expenses: Operating expenses were $1.459 million, up from $1.410 million. R&D fell to $470,283 from $631,034; general and administrative expense rose to $882,798 from $678,481, principally on higher legal, professional and public-company costs. Aquaculture costs declined to $78,280 from $98,050.
- Cash flow: Operating activities used $1.309 million, versus $1.144 million used a year earlier. Investing activities provided $4.473 million, mainly from $4.5 million of Treasury-bill maturities and sales. Cash and cash equivalents increased to $7.365 million from $4.226 million.
- Liquidity and balance sheet: Cash, cash equivalents and short-term Treasury bills totaled $8.964 million at quarter-end; working capital was $8.870 million. Total assets were $10.500 million and shareholders’ equity was $9.908 million. Current liabilities were $592,023, including $80,000 deferred revenue. No debt balance is reported in the supplied balance sheet.
- Other metrics: Accumulated deficit was $51.837 million. Capital expenditures were approximately $6,000. Basic and diluted loss per share was $0.26 versus $0.93; weighted-average shares were 5,330,715 versus 1,502,870. The filing states historical share amounts reflect a May 2018 one-for-seven reverse split.
Changes, outlook and risks
- Management plans to fund the next twelve months with cash and investments on hand and product sales. It expects additional losses while investing in R&D, manufacturing and market development, and says spending can be adjusted. Additional debt or equity financing or strategic arrangements may be considered; no assurance of financing is provided.
- KLH sales depend on the pace of third-party clinical studies and may fluctuate by quarter. Three customers accounted for 86% of current-quarter product sales, versus 98% a year earlier; North America represented 81% of sales versus 27%, while Europe represented 19% versus 73%. Two customers accounted for 82% of accounts receivable at December 31.
- On December 31, 2018, the company and its joint-venture partner agreed to dissolve and liquidate Neostell by mutual consent after the company decided not to pursue the project. The quarter includes an approximately $30,000 impairment charge in general and administrative expense; the equity investment was reduced to zero.
- The company adopted ASC 606 on October 1, 2018, with no impact on historical interim financial statements. It reported no material change in risk factors from its prior Form 10-K, no material off-balance-sheet arrangements, and no material legal proceedings outside the ordinary course.
- Risks identified include funding availability, third-party clinical-study timing and success, product-market acceptance, strategic partnerships, manufacturing scale-up, intellectual-property protection, regulation, competition, foreign-exchange exposure and reliance on key personnel. Management concluded disclosure controls were effective as of December 31, 2018.
Most important facts to verify
- Confirm the issuer and reporting period: the supplied text is Stellar Biotechnologies’ Form 10-Q, not Edesa Biotech’s.
- Assess whether the $8.964 million of cash and Treasury bills and expected product sales support management’s stated twelve-month funding plan, given continuing operating cash use and expected losses.
- Review customer concentration and clinical-trial dependencies, including the effect of fluctuating KLH sales on revenue and cash flow.
- Confirm the status and remaining obligations, if any, related to the Neostell dissolution and liquidation.
- Consider potential dilution from outstanding warrants: 2,049,808 remained at December 31, 2018, with a weighted-average exercise price of $5.27.